←
Uromigos2,776 posts
Uromigos avatar✓

Uromigos ✓

@Uromigos

The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.

◷ Joined February 2017▧ 812 Photos and videos
Uromigos avatar
Uromigos@Uromigos·19h

Can patients with muscle-invasive bladder cancer avoid radical cystectomy? From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸 Listen to the full discussion ⬇️ 🎧 Apple: apple.co/4t9r8Ps 🎧 Spotify: bit.ly/4iPpf6Q

Post attachment
Uromigos avatar
Uromigos@Uromigos·21h

How much should ctDNA and utDNA influence treatment decisions in muscle-invasive bladder cancer? From risk assessment to treatment selection, our expert panel explores the evolving role of biomarkers 👀 Listen to the full discussion, recorded live at #UromigosLive in Nashville ⬇️ 🎧 Apple: apple.co/4f9n0sM 🎧 Spotify: bit.ly/4kkYfxl

Post attachment
Uromigos avatar
Uromigos@Uromigos·Nov 16

That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup. Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️

Post attachment
OncoAlert avatar
⟳ Uromigos retweeted
OncoAlert@OncoAlert·Nov 14

The OncoAlert 🚨Coverage of #UromigosLive 🎸 VOLGA: Do We Need Adjuvant EV? KEYNOTE-905 and KEYNOTE-B15 showed that perioperative EV-pembro works in MIBC. But both trials gave EV before and after surgery. Does every patient need both? Dr. Matthew Galsky🇺🇸 (@MattGalsky from Mount Sinai) and and Dr. Jonathan Rosenberg🇺🇸 @DrRosenbergMSK from @MSKCancerCenter break down VOLGA: ▪️ Cisplatin-ineligible MIBC ▪️ 3 cycles of EV + durvalumab → cystectomy → adjuvant durvalumab only (no adjuvant EV) ▪️ Significant benefit vs cystectomy alone. The regimen was FDA approved the day of the session ▪️ The tremelimumab arm improved EFS but not OS, and wasn’t approved 🔍 Compared with EV-pembro, the confidence intervals overlap across the major endpoints, though EV-pembro’s point estimates are slightly lower. 📌 His framing: there are now two approaches, EV before and after surgery, or EV before surgery only. The open question is who needs more and who needs less, and ctDNA plus pathologic stage may help answer it. VOLGA’s post-op ctDNA data is expected at an upcoming meeting. 👇 Watch the full conversation #BladderCancer #MIBC #GUOnc #OncoAlert @uromigos @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan

4:24
Uromigos avatar
Uromigos@Uromigos·Nov 16

Is platinum chemotherapy entering a new era in muscle-invasive bladder cancer? Recorded live at #UromigosLive in Nashville, our expert panel revisited 15 years of clinical trials, debated the evolving role of chemotherapy and immunotherapy, and explored what's next for MIBC treatment 🎸 Listen to the full discussion 🎧 Spotify: bit.ly/4iKPSKj Apple: apple.co/4t59350

Post attachment
OncoAlert avatar
⟳ Uromigos retweeted
OncoAlert@OncoAlert·Nov 14

OncoAlert🎙️ Live from Broadway, Nashville at #UromigosLIVE 2026 @tompowles1 🇬🇧 & @brian_rini 🇺🇸break down PROTEUS 🔹 Main trial (ASCO plenary): apalutamide + ADT around radical prostatectomy improved MFS. But the control arm already used ADT, and most events were found on PSMA PET 🔹 Sub-study (ESMO, ~400 pts): same experimental arm vs surgery alone. The curves separate even more, but follow-up is shorter ❓ Is it just proof that hormone therapy works, or practice-changing? Is MFS enough without OS? #ProstateCancer @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan

3:24
Tom Powles avatar
⟳ Uromigos retweeted
Tom Powles@tompowles1·Nov 15

Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer. The trial achieved impressive PFS but not OS (with some subgroup inconsistency). We see PFS achieve approvals without OS in other tumours including all 3 GU cancers. It’s not always easy to predict the future in terms of results or regulatory approvals, but the class of drug seems broadly active. VEFF/PD1s are in R3 trials in bladder cancer with EV. @OncoAlert google.com/goto?url=CAESwgEB…

Uromigos avatar
Uromigos@Uromigos·Nov 15

And in the end Belgium wins #uromigosLive @OncoAlert 🇧🇪 Belgium 🇧🇪 Belgium 🇧🇪 Belgium 🇧🇪 🏆 🏆. 🏆 🏆 m (with a little help from France 🇫🇷 )

Post attachment
3:29
Sumanta K. Pal, MD, FASCO avatar
⟳ Uromigos retweeted
Sumanta K. Pal, MD, FASCO@montypal·Nov 13

Brilliant summary from @tompowles1 & @brian_rini ahead of @Uromigos. Really looking fwd to discussing the data on Saturday at #UromigosLive 2026. As Brian points out, response rates are high with #XMab819 in a heavily refractory population of patients - 45% in those who have received prior checkpoint at at least 2 VEGF-TKIs in one of our analyses. Agree that we need to brainstorm ways to move these strategies ahead quickly for our #kidneycancer patients.

5:26